MedTrace Logo

REACH2: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire

NCT05016895 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 767535

Last updated 2025-03-04

No results posted yet for this study

Summary

REACH2 is a three-year implementation research study designed to examine the implementation through a mass drug administration platform of bi-annual single-dose azithromycin to reduce child mortality among children ages 1 to 11 months who reside in high child mortality settings.

Conditions

  • Child Mortality

Interventions

DRUG

Single-dose azithromycin

Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.

Sponsors & Collaborators

  • Ministry of Health, Ivory Coast

    collaborator UNKNOWN

  • FHI 360

    lead OTHER

Principal Investigators

  • Lisa Dulli, PhD · FHI 360

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Month
Max Age
11 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-27
Primary Completion
2024-06-30
Completion
2024-07-31

Countries

  • Côte d’Ivoire

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05016895 on ClinicalTrials.gov